U.S. Non-alcoholic Steatohepatitis Biomarkers Market To Reach $2.84 Billion By 2030

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends

The U.S. non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 2.84 billion by 2030 and is anticipated to expand at a CAGR of 23.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome contribute to the growing incidence of non-alcoholic steatohepatitis (NASH) in the U.S. population, which is fueling the demand for biomarkers. According to the National Library of Medicine, Cirrhosis and chronic liver disease (CLD) are major worldwide health burdens leading to 1.1 million deaths yearly, and CLD ranks as the eleventh most common cause of death worldwide.

The market is experiencing significant innovation, primarily focused on developing novel biomarkers to accurately diagnose and monitor NASH, a liver disease caused by fat accumulation. These biomarkers are crucial for early detection, disease progression monitoring, and assessing treatment response in NASH patients. Companies and research institutions are actively developing these biomarkers to address the limitations of existing diagnostic tools and provide more accurate information about the disease status.

Digital health technologies such as mobile apps, wearable devices, and artificial intelligence (AI) algorithms are being used to develop novel biomarkers for NASH diagnosis and monitoring. The use of extensive clinical data sets and the latest advancements in AI applications have created a strong potential to increase diagnostic accuracy. In June 2023, the Kinetix Group’s NASHNET network of excellence published a white paper that explored current perspectives and potential future applications of biomarkers for diagnosing and staging non-alcoholic fatty liver disease (NAFLD) and NASH.

 Request a free sample copy or view report summary: U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights

• Based on the type, the serum biomarkers segment dominated the market with a revenue share of 32.5% in 2023. The ability of serum biomarkers to provide valuable insights into disease progression and treatment response has made them indispensable tools for healthcare professionals

• The hepatic fibrosis biomarkers is expected to grow at the fastest rate during the forecast period due to the rising number of obesity, people following sedentary lifestyles, and metabolic syndromes

• The pharma & CRO industry in end-use segment dominated the market in 2023. This growth is attributable to the increasing healthcare expenditure and awareness in the U.S., particularly for chronic and complex diseases

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Segmentation

Grand View Research has segmented the U.S. non-alcoholic steatohepatitis biomarkers market based on type, end-use, and region:

U.S. Non-alcoholic Steatohepatitis Biomarkers Type Outlook (Revenue, USD Million, 2018 - 2030)

• Serum Biomarkers

• Hepatic Fibrosis Biomarkers

• Apoptosis Biomarkers

• Oxidative Stress Biomarkers

• Others

U.S. Non-alcoholic Steatohepatitis Biomarkers End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharma & CRO Industry

• Hospitals

• Diagnostic Labs

• Academic Research Institutes

U.S. Non-alcoholic Steatohepatitis Biomarkers Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Non-alcoholic Steatohepatitis Biomarkers Market

• GENFIT

• Prometheus Laboratories

• Siemens Medical Solutions USA, Inc.

• Quest Diagnostics

• AstraZeneca

• Laboratory Corporation of America Holdings

• Pfizer, Inc.

• Bristol-Myers Squibb Company